GoodFellas Big Board Catalyst and Chart Plays

[xtremezz]

ACRX Reports Statistically Significant Data from NanoTab PCA Phase 3

Had a strong close yesterday:

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) announced that top-line data from its previously announced open-label, active-comparator study of its lead product candidate, the Sufentanil NanoTab PCA System, will be featured in poster presentations to be held at the 66th annual New York State Society of Anesthesiologists PostGraduate Assembly meeting in New York City to be held December 14-18, 2012. The poster is authored by Dr. Timothy Melson of Helen Keller Hospital, Sheffield, AL, Dr. Alparslan Turan of The Cleveland Clinic, Cleveland, OH, and Dr. Pamela Palmer of University of California, San Francisco, and Chief Medical Officer of AcelRx Pharmaceuticals and will be presented on Sunday, December 16, 2012 from 11:00 AM to 1:00 PM at the New York Marriott Marquis.

http://www.streetinsider.com/Corporate+News/AcelRx+(ACRX)+Reports+Statistically+Significant+Data+from+NanoTab+PCA+Phase+3/7948743.html